AstraZeneca’s MedImmune has formed an exclusive global partnership with AgonOx to develop tumour-specific T-cell immunity stimulators for the potential treatment of cancer based on AgonOx’s OX40 platform. MedImmune will lead further preclinical and clinical studies and will also support ongoing OX40 research at Providence Cancer Center, where the initial preclinical and clinical development of OX40 has been conducted.